`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`AMERICAN EXPRESS COMPANY, AMERICAN EXPRESS TRAVEL
`RELATED SERVICES COMPANY, INC., COMPASS BANK,
`DISCOVER FINANCIAL SERVICES, DISCOVER BANK,
`DISCOVER PRODUCTS INC., and
`STATE FARM MUTUAL AUTOMOBILE INSURANCE COMPANY,
`Petitioners,
`
`v.
`
`MAXIM INTEGRATED PRODUCTS, INC.,
`Patent Owner.
`____________
`
`Case CBM2015-00101
`Patent 6,105,013
`____________
`
`PATENT OWNER’S
`REQUEST FOR REHEARING OF DECISION INSTITUTING
`COVERED BUSINESS METHOD PATENT REVIEW
`
`
`
`
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`TABLE OF CONTENTS
`
`
`
`
`
`THE DECISION MISAPPREHENDED AIA § 18’S REQUIREMENT
`THAT A CBM PATENT IS “A PATENT THAT CLAIMS A METHOD
`OR CORRESPONDING APPARATUS FOR PERFORMING . . .
`OPERATIONS USED IN THE PRACTICE, ADMINISTRATION, OR
`MANAGEMENT OF A FINANCIAL PRODUCT OR SERVICE”. ................. 3
`
`A. The Board Relied On The Specification, Rather Than The Claims. ............ 5
`
`B. The Statute Requires That The Patent Claim An Invention
`“For” Operations “Used In . . . Financial Products Or Services,” Not
`Merely “Encompassing” Such Operations. ................................................... 7
`
`C. The Board Improperly Rejected The “Technological Invention”
`Exception To Institution Based On Extrinsic Trial Evidence. ................... 12
`
`1. The “technological” exception is a threshold determination. .............. 13
`
`2. The exception cannot be decided based on trial testimony. ................. 13
`
`CONCLUSION .................................................................................................. 15
`
`
`
`i
`
`
`
`
`
`
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`TABLE OF AUTHORITIES
`
`
`
`Cases
`
`Achates Reference Publ., Inc. v. Apple Inc., --- F.3d ----,
`2015 U.S. App. LEXIS 17183 (Fed. Cir. Sep. 30, 2015) ...................................... 2
`
`Pall Corp. v. Hemasure, Inc., 181 F.3d 1305 (Fed. Cir. 1999) ............................... 11
`
`Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc) ......................... 14
`
`Versata Dev. Group, Inc. v. SAP Am., Inc., 793 F.3d 1306 (Fed. Cir. 2015),
`reh’g & reh’g en banc denied (Fed. Cir. Oct. 15, 2015) ...................................2, 3
`
`Wilson Sporting Goods Co. v. Hillerich & Bradsby Co., 442 F.3d 1322
`(Fed. Cir. 2006) ............................................................................................. 11, 12
`
`Administrative Determinations
`
`Fairchild Semiconductor Corp. v. In-Depth Test LLC, CBM2015-00060,
`Paper 11 (PTAB Aug. 3, 2015) ............................................................................ 11
`
`Liberty Mut. Ins. Co. v. Progressive Cas. Ins. Co., CBM2012-00003,
`Paper 15 (PTAB Feb. 12, 2013)........................................................................... 15
`
`Motorola Mobility LLC v. Intellectual Ventures I LLC, CBM2014-00083,
`Paper 17 (PTAB Aug. 6, 2014) ............................................................................ 15
`
`Sony Corp. of Am. v. Network-1 Techs., CBM2015-00078,
`Paper 7 (PTAB Jul. 1, 2015) ........................................................................... 8, 11
`
`Statutes
`
`Leahy-Smith America Invents Act of 2011, Pub. L. No. 112-29,
`125 Stat. 284, 327, § 14 .................................................................................. 9, 10
`
`Leahy-Smith America Invents Act of 2011, Pub. L. No. 112-29,
`125 Stat. 284, 327, § 14(a) .............................................................................. 9, 10
`
`
`
`ii
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`Leahy-Smith America Invents Act of 2011, Pub. L. No. 112-29,
`125 Stat. 284, 330, § 18 ................................................................................ 2, 3, 9
`
`Leahy-Smith America Invents Act of 2011, Pub. L. No. 112-29,
`125 Stat. 284, 330, § 18(a)(1)(E) ......................................................................... 13
`
`Leahy-Smith America Invents Act of 2011, Pub. L. No. 112-29,
`125 Stat. 284, 331, § 18(d)(1) ...................................................................... passim
`
`Regulations and Rulemaking
`
`37 C.F.R. § 42.207(c) ............................................................................................... 14
`
`USPTO Guidance Document, “Tax Strategies Training Examples,”
`www.uspto.gov “Patents Examination Area” (last visited Sep. 28, 2015) .......... 10
`
`USPTO Patent And Trademark Appeal Board, Standard Operating
`Procedure No. 1 (rev. 14) ...................................................................................2, 3
`
`USPTO, Amendments to the Rules of Practice; Proposed Rules, 80 Fed. Reg.
`50,719 et seq. (Aug. 20, 2015) ............................................................................... 2
`
`USPTO, Manual of Patent Examining Procedure
`(9th Ed. Mar. 2014) § 2124.01 ............................................................................... 9
`
`Legislative History
`
`157 Cong. Rec. H4421 (June 22, 2011) (Statement of Rep. Smith) ....................... 10
`
`157 Cong. Rec. S1053, 1053 (Mar. 1, 2011) (Statement of Sen. Schumer)............ 10
`
`157 Cong. Rec. S1363 (daily ed. Mar. 8, 2011) (Statement of Sen. Schumer) ....... 15
`
`
`
`
`
`
`
`
`
`
`
`
`
`iii
`
`
`
`
`
`
`
`
`
`EXHIBIT LIST
`
`Exhibit 2001
`
`Exhibit 2002
`
`Exhibit 2003
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`Order of Dismissal With Prejudice, Maxim Integrated
`Prods., Inc. v. Navy Fed. Credit Union, Civil Action
`No. 5:14-cv 01032-XR (W.D. Tex. May. 18, 2015)
`
`Confidential Settlement Agreement between Maxim
`Integrated Products and Navy Federal Credit Union
`
`Disclaimer in Patent Under 37 CFR 1.321(a), U.S. Pat.
`No. 6,105,013, cls. 7, 14, 16 (09/041,190 Jul. 6, 2015)
`
`Exhibit 2004
`
`U.S. Patent No. 5,805,702 to Curry et al.
`
`Disclaimer in Patent Under 37 CFR 1.321(a), U.S. Pat.
`No. 5,940,510, cl. 2 (08/594,975 Jun. 19, 2015)
`
`Restriction Requirement, U.S. Patent No. 5,805,702
`(08/595,014 Jul. 21, 1997)
`
`Originally-filed claims, U.S. Patent No. 5,805,702
`(08/595,014 Jan. 31, 1996)
`
`Hearing Transcript, In re Maxim Integrated Products,
`Inc., Misc. No. 12-244 (MDL No. 2354) (W.D. Pa.
`Mar. 20, 2013) (excerpt)
`
`Declaration of Nathan Lowenstein in support of Patent
`Owner Maxim Integrated Products, Inc.’s Motion For
`Pro Hac Vice Admission Of Nathan Lowenstein Under
`37 C.F.R. § 42.10(c)
`
`iv
`
`
`
`Exhibit 2005
`
`Exhibit 2006
`
`Exhibit 2007
`
`Exhibit 2008
`
`Exhibit 2009
`
`
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`Patent Owner respectfully petitions for rehearing of the Board’s October 2,
`
`2015 decision instituting covered business method (“CBM”) patent review. Paper
`
`17 (“Institution Decision,” “Decision” or “ID”).
`
`The Decision found that the Petition showed that claims 1 and 9
`
`demonstrates that the Patent is a CBM patent, and on that basis found standing for
`
`institution of review under the CBM standing statute, AIA § 18(d)(1). ID 12.
`
`Rehearing is sought based on two errors, each dispositive of CBM standing.
`
` First, the ruling misapprehended § 18(d)(1)’s “claims” requirement, by
`
`interpreting it to require merely that CBM patents have a claim that
`
`“encompasses” operations used in practicing, administering, or managing
`
`financial products or services, and specification disclosure that the invention is
`
`“intended” for such operations; rather than requiring that it claim, by explicit or
`
`implicit claim limitations, an invention for performing such operations.
`
` Second, the ruling misapprehended § 18(d)(1)’s “technological inventions”
`
`standing exception, effectively nullifying that exception, by rejecting it on the
`
`basis of extrinsic trial evidence to which Patent Owner could not fairly respond.
`
`“A request for rehearing is an opportunity to address whether a panel
`
`misapprehended or overlooked a matter in rendering its opinion, which may
`
`include identification of conflicting Board or court decisions[.]” USPTO,
`
`
`
`1
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`to
`
`the
`
`Rules
`
`of
`
`Practice;
`
`Proposed
`
`Rules,
`
`
`Amendments
`
`80 Fed. Reg. 50,719, 50,740 (Aug. 20, 2015). The Office has issued many CBM
`
`standing decisions that are in striking tension with this Decision. POPR 6-8, 13-
`
`15, 21-24. It thus appears that “a substantial difference of opinion among judges
`
`exists” on the Board with respect to the scope of CBM standing. PTAB Standard
`
`Operating Procedure No. 1 (rev. 14) § III-A-2. This Office’s reviewing Court has
`
`addressed CBM standing in only one case, which shed little light on that scope,
`
`except to clarify that the determination is reviewable on appeal. Versata Dev.
`
`Group, Inc. v. SAP Am., Inc., 793 F.3d 1306, 1319 (Fed. Cir. 2015), reh’g & reh’g
`
`en banc denied (Fed. Cir. Oct. 15, 2015). Thus, since the AIA’s passage in 2011, a
`
`settled interpretation of § 18’s CBM standing provisions has yet to develop.
`
`The scope of statutory standing under § 18 is a vitally important question. It
`
`concerns “the fundamental limitation of the Board’s . . . ultimate authority to
`
`invalidate only CBM patents in a CBMR proceeding.” Achates Reference Publ.,
`
`Inc. v. Apple Inc., --- F.3d ----, 2015 U.S. App. LEXIS 17183, *11-12 (Fed. Cir.
`
`Sep. 30, 2015) (citations omitted). Because the decision on institution in this case
`
`so clearly turns on how broadly AIA § 18 should be interpreted, it is an appropriate
`
`case for the Office to reconcile its past decisions on the subject of CBM standing,
`
`and set forth a reasonable, consistent, and supported interpretation of Section 18.
`
`
`
`2
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`Yesterday, in Versata, the Office’s reviewing court let stand its decision that
`
`CBM standing determinations are appealable. If necessary, the errors raised here
`
`will come before the court for correction. As discussed herein, the Decision’s
`
`broad, strained interpretation transgresses the bounds of reasonable interpretation
`
`of AIA § 18; is not of long standing; decides novel legal questions at an
`
`intermediate level of the Office without relying on its specialized expertise;
`
`contravenes Congress’s limiting intent; and is inconsistent with prior Office
`
`interpretations of this provision and of related provisions. Rehearing is merited.
`
`An expanded panel on rehearing is respectfully suggested. SOP 1 § III-C.
`
`THE DECISION MISAPPREHENDED AIA § 18’S REQUIREMENT THAT
`A CBM PATENT IS “A PATENT THAT CLAIMS A METHOD OR
`CORRESPONDING APPARATUS FOR PERFORMING . . . OPERATIONS
`USED IN THE PRACTICE, ADMINISTRATION, OR MANAGEMENT OF
`A FINANCIAL PRODUCT OR SERVICE”
`
`AIA § 18(d)(1) requires that a CBM patent be “a patent that claims a method
`
`or corresponding apparatus for performing . . . operations used in the practice,
`
`administration, or management of a financial product or service.” This provision
`
`should be interpreted to require that a CBM patent have one or more claims limited
`
`to an invention that is, at least, an invention “for performing . . . operations used in
`
`the practice, administration, or management of a financial product or service.”
`
`Under a valid interpretation, standing is absent. POPR 6-11, 25-28.
`
`
`
`3
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`The Institution Decision found standing under an unreasonably broad
`
`interpretation of this provision. Contrary to the statutory text, and the Office’s
`
`positions elsewhere, the Decision interpreted this provision to require only a claim
`
`that “encompasses” operations used in the practice, administration, or management
`
`of a financial product or service and is described in the specification as “intended”
`
`to be used in such operations. ID 12-13. This interpretation, which effectively
`
`rewrites the “claims” requirement into a “reads on and mentions” requirement, is
`
`unreasonably broad. AIA § 18(d)(1) uses the word “claims” for a reason. It limits
`
`CBM standing based on what the patent “claims”1—not based on unclaimed
`
`examples or aspirational intentions in the specification.
`
` The Decision’s
`
`interpretation would permit the Office to find CBM standing whenever operations
`
`used in financial services are mentioned anywhere in the patent, regardless of what
`
`the patent claims. If that were so, a claim reciting simply “a ball-point pen” could
`
`suffice for CBM standing—so long as the patent specification lauded the use of
`
`such pens for bookkeeping, and banks using them were sued for infringement.
`
`Such an interpretation is not only inconsistent with other Office determinations; it
`
`would be hiding a regulatory elephant in a statutory mousehole, for it would grant
`
`the Board CBM jurisdiction over wide swaths of patents bearing no resemblance to
`
`
`1 Emphases herein are added unless otherwise indicated.
`4
`
`
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`conventional “business methods”—like the Patent here, which even the Decision
`
`admits has claims laden with “technological” limitations. ID 16; POPR 22, 36-37.
`
`A. The Board Relied On The Specification, Rather Than The Claims.
`
`In finding standing, the Institution Decision quite candidly finds that the
`
`[P]atent meets the financial product or service requirement “as evidenced by the
`
`financial embodiments disclosed in the specification.” ID 12. It then quotes a
`
`series of statements from the written description, which it says “show[] that the
`
`system recited in independent claim 1 encompasses financial products and services
`
`and is intended to be used for such products and services,” and that “embodiments
`
`involving secure financial transactions, including payments and deposits, are the
`
`central focus of the specification.” ID 12. During this analysis, the Decision does
`
`not quote the claims. Id. But see POPR 6-9, 16. Nor does it specify how the
`
`“central focus” of a specification might be determined—or how it can affect what
`
`the patent claims if it does not affect the claims’ limitations.
`
`The closest the Institution Decision comes to finding anything financial in
`
`the claims comes next, where it says “the relationship between the portions of the
`
`Specification cited in the Petition and the claim language—particularly the ‘secure
`
`transaction integrated circuit’ of independent claims 1 and 9—is evident from the
`
`Petition.” ID 13. And just what is that “relationship”? The Decision explains that
`
`
`
`5
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`[t]he cited portions of the specification, outlined above, make clear
`that the “secure transaction integrated circuit” recited in claims 1 and
`9 is intended to be used for secure financial transactions. The
`‘input/output circuit,’, for exchanging the recited ‘information’ (claim
`1) and ‘data’ (claim 9) encompasses circuitry for exchanging a cash
`equivalent or monetary value. A claimed system that transfers a cash
`equivalent or monetary value manages a financial product, and
`providing such transfers delivers a financial service.
`
`Id. But a “claimed system” can only be said to “transfer” something if the claims
`
`require that it be transferred. Otherwise, that is merely unclaimed additional
`
`activity. Patent Owner could agree with the Board’s last sentence quoted above if
`
`the claims contained limitations limiting the invention to being “used for secure
`
`financial transactions,” or requiring that the recited “data” “encompass[] circuitry
`
`for exchanging ‘a cash equivalent or monetary value.’” Such limitations would
`
`make it a claim that “claims [an invention] for . . . operations used in the practice,
`
`administration, or management of a financial products or service,” as AIA
`
`§ 18(d)(1) requires. However, the Board never even purports to construe claim 1
`
`to have any such limitations. And it does not have any. POPR 19-22, 26-31.
`
`To be sure, had the Board construed the claims to have implicit financial
`
`limitations, it would have had to address Patent Owner’s detailed arguments why
`
`such constructions would be erroneous. Id. But it nowhere addressed them.
`
`
`
`6
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`The Statute Requires That The Patent Claim An Invention “For”
`Operations “Used In . . . Financial Products And Services,” Not
`Merely “Encompassing” Or “Intended” For Such Operations.
`
`
`B.
`
`The Institution Decision recognizes that it does not identify any financial
`
`limitations in the claims. ID 14. Nevertheless, it finds CBM standing, by
`
`announcing that it interprets AIA § 18(d)(1) to not require any such limitations. Id.
`
`The Decision holds that it would “overstate the financial product or service
`
`requirement” of AIA § 18(d)(1) to require that the claims be “limited to,
`
`specifically directed to, or specific to financial products or services.” Id. Instead:
`
`[t]o satisfy the definition of a covered business method patent in
`§ 18(d)(1) of the AIA, the patent need only “claim[] a method or
`corresponding apparatus for performing data processing or other
`operations used in the practice, administration, or management of a
`financial product or service.” AIA § 18(d)(1) (emphases added). Thus,
`the express statutory language does not mandate that a claim be
`specific or limited to a financial product or service. Instead, it requires
`only that a claim be “used in the practice, administration, or
`management” of such a product or service.
`
`Id. (emphasis by Board). In an attempt to support this surprising interpretation, the
`
`Decision points to statements by individual Senators in the AIA legislative history,
`
`which it says “indicate[] that to meet the [CBM standing] requirement, the patent
`
`must be ‘intended to be used in the practice, administration, or management of
`
`
`
`7
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`financial services or products,’ but ‘need not recite a specific financial product or
`
`service’” and may “‘encompass not only patents claiming the financial product or
`
`service itself, but also patents claiming activities that are financial in nature,
`
`incidental to a financial activity or complementary to a financial activity.’” Id. at
`
`14 (citations and internal markings omitted) (quoting Sens. Schumer and Leahy).
`
`This interpretation of AIA § 18(d)(1) is unreasonably broad. As already
`
`noted, under this interpretation a claim to “a ball-point pen” can straightforwardly
`
`suffice to generate CBM standing, so long as the patent specification lauds the use
`
`of such pens for bookkeeping (and banks using them have been sued). The Board
`
`has already squarely rejected just such a broad interpretation of AIA § 18(d)(1),
`
`noting that it “‘would mean that any patent claiming something that can be used in
`
`connection with a financial service (e.g., an Ethernet cable, a generic computer
`
`monitor, or even a ball point pen) would be eligible for covered business method
`
`patent review, regardless of what the patent claims,’” and insisting instead that
`
`“language [in the claims] relating to a financial product or service” is required.
`
`Sony Corp. of Am. v. Network-1 Techs., CBM2015-00078, Paper 7 (PTAB Jul. 1,
`
`2015), at 9, 12; POPR 8. Sony is in close accord with many other earlier Board
`
`decisions, which have insisted that CBM standing must rest on the language of the
`
`claims. POPR 6-8, 13, 17-18, 25, 27, 31-33 (quoting numerous Board decisions).
`
`
`
`8
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`This interpretation does not merely contradict earlier Board interpretations
`
`of AIA § 18. It also bears no resemblance to Office interpretations of other,
`
`similar AIA provisions—in particular AIA § 14, which limits the patentability of
`
`tax preparation methods. AIA § 14(a) specifies that “any strategy for reducing,
`
`avoiding, or deferring tax liability . . . shall be deemed insufficient to differentiate
`
`a claimed invention from the prior art.” It is instructive to see how the Office has
`
`interpreted AIA § 14(a)’s requirement that a tax strategy patent be one claiming a
`
`“strategy for reducing, avoiding, or deferring tax liability”—for it stands in sharp
`
`contrast to the Decision’s interpretation of the provisions of AIA § 18(d)(1).
`
`When it applies AIA § 14, the Office determines whether a claim is a tax
`
`strategy claim by looking to the claims’ recited limitations. The Office instructs
`
`examiners to apply § 14 by “[i]dentify[ing] any limitations relating to a tax
`
`strategy,” and that such “claim limitations directed to a tax strategy should not be
`
`given patentable weight.” M.P.E.P. § 2124.01. Its official training guide reads:
`
`Issues under Section 14 arise where the claim recites a plan for
`reducing, avoiding, or deferring a tax liability. The determination of
`whether a tax strategy is involved is not only a claim-by-claim
`analysis, but also a limitation-by-limitation analysis . . . . [If a]
`determining step does not explicitly or inherently require the
`performance of any action towards reducing, avoiding, or deterring
`tax liability, the determining step would not be considered to be
`
`
`
`9
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`within the prior art per Section 14. . . . [If] no limitations in the claim
`are directed to a tax strategy for reducing, avoiding or deferring a tax
`liability as no steps are taken that explicitly or implicitly change any
`such liability, . . . the method does not limit the use of any tax
`strategy by any taxpayer or tax advisor and Sec. 14 does not apply.
`
`USPTO Guidance Document,
`
`“Tax Strategies Training Examples,”
`
`www.uspto.gov “Patents Examination Area” (last visited Oct. 6, 2015). Thus,
`
`under AIA § 14, the Office determines whether a patent claims a strategy “for
`
`reducing, avoiding or deferring a tax liability” based on the claim’s limitations that
`
`“require” such actions—not based on whether the claims “encompass” such
`
`actions, or the specification has a “focus” on such actions, or the invention is
`
`“intended” for such actions. In other words, the Office’s interpretation of claimed
`
`“strategies for” affecting liability under AIA § 14(a) contrasts very sharply with
`
`the Institution Decision’s interpretation of the “claims” requirement of § 18(d)(1).
`
`As for the legislative history, these statements of individual Senators must
`
`be weighed in balance with other legislative assurances—including statements by
`
`the same Senators—that the scope of the CBM statute was narrow. E.g., 157
`
`Cong. Rec. S1053, 1053 (Mar. 1, 2011) (Statement of Sen. Schumer) (“In response
`
`to concerns that earlier versions of the [CBM] amendment were too broad, we have
`
`modified it so it is narrowly targeted. We want to make sure to capture the
`
`
`
`10
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`business method patents which are at the heart of the problem and avoid any
`
`collateral circumstances.”); 157 Cong. Rec. H4421 (June 22, 2011) (Statement of
`
`Rep. Smith) (CBM statute is “a pilot program to review a limited group of
`
`business method patents”). Even taken literally, the legislative history cited by the
`
`Decision would still require that the patent “claim”—not merely “encompass”—
`
`incidental or complementary activities. See POPR 6-8. And once again, in other
`
`cases the Board has interpreted the legislative history very differently. See, e.g.,
`
`Sony, CBM2015-00078, Paper 7 at 12; Fairchild Semiconductor Corp. v. In-Depth
`
`Test LLC, CBM2015-00060, Paper 11 (PTAB Aug. 3, 2015) at 9 (same).
`
`Finally, the Board cites “Patent Owner’s assertion of the [Patent] against
`
`numerous financial institutions and banks” as “a factor weighing in favor of a
`
`conclusion
`
`that
`
`the [Patent]
`
`is ‘used
`
`in
`
`the practice, administration, or
`
`management’ of financial products or services.” ID 15. Again, Patent Owner
`
`would agree—if such evidence supported construing the claims to include
`
`financial limitations. “Although the construction of the claim is independent of
`
`the device charged with infringement,” Pall Corp. v. Hemasure, Inc., 181 F.3d
`
`1305, 1308 (Fed. Cir. 1999), “knowledge of [the accused] product or process
`
`provides meaningful context for . . . claim construction,” Wilson Sporting Goods
`
`Co. v. Hillerich & Bradsby Co., 442 F.3d 1322, 1326 (Fed. Cir. 2006). But
`
`
`
`11
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`although the Patent has been asserted against banks’ activities, the Board “may not
`
`use the accused product or process as a form of extrinsic evidence to supply
`
`limitations for patent claim language.” Wilson, 442. F.3d at 1331. Moreover, once
`
`more the Institution Decision is inconsistent with other Board decisions, which
`
`squarely reject the argument that the assertion of generally-applicable claims
`
`against financial operations can transform a patent into a CBMP. POPR 21-22.
`
`A reasonable interpretation of AIA § 18(d)(1) would require the patent to
`
`have claim limitations restricting it to a method or corresponding apparatus for
`
`performing data processing or other operations used in the practice, administration,
`
`or management of a financial product or service—not merely that its scope
`
`encompass such an invention. And litigation activity should not affect CBM
`
`standing except as it affects how the claims must be construed.
`
`C. The Board Improperly Rejected The “Technological Invention”
`Exception To Institution Based On Extrinsic Trial Evidence.
`
`The Institution Decision adopts Petitioner’s position that the Patent is not a
`
`“patent[] for technological inventions—” a category expressly “except[ed]” from
`
`CBM standing under AIA § 18(d)(1). ID 15-18. The Decision holds that “on the
`
`record before [it],” Petitioners’ position is supported—relying first and foremost on
`
`“testimony from Peter Alexander, Ph.D.,” Petitioner’s expert declarant. ID 16.
`
`
`
`12
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`The Board misapprehends this exception. It is unreasonable to interpret an
`
`express exception to institution to depend on a record to be developed at trial.
`
`Moreover, Patent Owner was barred from submitting its own testimony and had no
`
`right to cross-examine Petitioners’ “expert.” Thus, rejecting this exception based
`
`on Dr. Alexander’s hearsay was unreasonable, as well as unfair. POPR 38-39.
`
`1.
`
`The “technological” exception is a threshold determination.
`
`The Decision inexplicably asserts that the “technological” exception does
`
`not bar institution “on the record before us.” ID 16-17. This fundamentally
`
`misapprehends the exception. AIA § 18(a)(1)(E) says that “[t]he Director may
`
`institute a transitional proceeding only for a patent that is a covered business
`
`method patent.” AIA § 18(d)(1) grants “patents for technological inventions” an
`
`express “except[ion]” from such “institut[ion].” Therefore, the determination
`
`whether or not the technological exception applies cannot ordinarily be made on a
`
`preliminary-record basis, awaiting further development of “the record before” it.
`
`That would transmute this express “except[ion]” of “technological inventions”
`
`from “institution” into a question to be developed at trial, after institution.
`
`2.
`
`The exception cannot be decided based on trial testimony.
`
`The Decision’s process in rejecting the technological exception was
`
`fundamentally improper for a second reason. In determining that the exception did
`
`
`
`13
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`not apply, the Decision relied, first and foremost, on the expert testimony
`
`submitted with the Petition. ID 16. Such expert testimony is paradigmatic
`
`“extrinsic evidence . . . generated at the time of and for the purpose of litigation”
`
`that “can suffer from bias that is not present in intrinsic evidence” and is a
`
`particularly poor basis for ascertaining the scope of the patent when “the expert’s
`
`opinion is offered in a form that is not subject to cross-examination.” Phillips v.
`
`AWH Corp., 415 F.3d 1303, 1318 (Fed. Cir. 2005) (en banc). Yet at the time of
`
`the Institution Decision, that was exactly the situation with respect to this
`
`testimony. Before institution, patent owners have no right to cross-examine
`
`Petitioner’s expert, and are barred from submitting rebuttal testimony. 37 C.F.R.
`
`§ 42.207(c). For these reasons, it would be fundamentally inappropriate for the
`
`Board to rely upon petitioners’ litigation testimony to reject the “technological”
`
`exception to institution. POPR 32-33. Yet that is exactly what the Institution
`
`Decision did. Relying on Dr. Alexander’s unrebuttable hearsay assertions to find
`
`that this exception did not apply was manifestly unfair.
`
`The technological-invention exception should be interpreted to turn, not on
`
`untestable, asymmetric, preliminary extrinsic evidence, but on the intrinsic
`
`evidence of whether the Office determined at the time of issuance that the claims’
`
`novelty turned on a technological innovation. That is the process suggested by
`
`
`
`14
`
`
`
`
`
` Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002USCBM
`
`
`numerous other Board decisions. See, e.g., Liberty Mut. Ins. Co. v. Progressive
`
`Cas. Ins. Co., CBM2012-00003, Paper 15 (PTAB Feb. 12, 2013) at 11-14;
`
`Motorola Mobility LLC v. Intellectual Ventures I LLC, CBM2014-00083, Paper 17
`
`(PTAB Aug. 6, 2014) at 4-5. And it is the process supported by the legislative
`
`history. See 157 Cong. Rec. S1363, S1364 (daily ed. Mar. 8, 2011) (Statement of
`
`Sen. Schumer) (indicating that test for when a patent is for a technology invention
`
`should be whether the Examiner’s determination of novelty for the claims
`
`“turn[ed] on a technological innovation over the prior art”).
`
`Under a reasonable interpretation of the technological exception, and a fair
`
`process for deciding the question, Petitioners’ rudimentary attempts to show that it
`
`did not apply were clearly insufficient. POPR 33-41. The Board should grant
`
`rehearing and find the “technological” exception was not shown to be inapplicable.
`
` CONCLUSION
`
`The Institution Decision’s interpretation of the CBM standing statute, AIA
`
`§ 18(d)(1), would gut both its “claim[ing]” requirement and its “technological”
`
`exception, and goes farther than the statute fairly allows. Rehearing should be
`
`granted to address the appropriate interpretation of CBM standing requirements.
`
`
`
`
`
`
`
`
`
`
`Date: October 16, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`______/Kenneth J. Weatherwax/_______
`Kenneth J. Weatherwax, Reg. No. 54,528
` Lowenstein & Weatherwax LLP
`15
`
`
`
`
`
`Case CBM2015-00101
`Patent 6,105,013
`Attorney Docket No. 150326-002 USCBM
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the following documents were served,
`
`by electronic mail on October 16, 2015, pursuant to the parties’ May 29, 2015
`electronic service agreement:
`
`
`PATENT OWNER’S REQUEST FOR REHEARING OF DECISION
`INSTITUTING COVERED BUSINESS METHOD PATENT REVIEW
`
`
`
`The names and addresses of the parties being served are as follows:
`
`David M. Tennant
`dtennant@whitecase.com
`WCAXPMaximCBMTeam@whitecase.com
`
`William F. Long
`blong@mckennalong.com
`
`
`
`
`Date: October 16, 2015
`
`
`Respectfully submitted,
`
`____/ Kenneth J. Weatherwax /______
`
`Kenneth J. Weatherwax
`Registration No. 54,528
`Attorney for Patent Owner